Group 1 - The core viewpoint of the article is that 哈三联 (Ha Sanlian) has announced a significant expected decline in net profit for 2025, projecting a loss between 375 million yuan and 315 million yuan, compared to a profit of 58.68 million yuan in the previous year, indicating a year-on-year decrease of 739.11% to 636.85% [2] Group 2 - The company reported that the expected net profit for 2025 will be in the range of -375 million to -315 million yuan [2] - The previous year's net profit was 58.68 million yuan, highlighting a stark contrast in financial performance [2] - The projected decline in net profit reflects a significant negative shift in the company's financial outlook [2]

Core Viewpoint - The company Hasi Lian (002900) is expected to report a significant loss in 2025, with a projected net profit attributable to shareholders ranging from -315 million to -375 million yuan, indicating a shift from profit to loss year-on-year [2] Financial Performance - The company's anticipated total revenue for 2025 is approximately 790 million yuan, reflecting a year-on-year decrease of 343 million yuan, or 30% [2] - The decline in revenue is attributed to the impact of national drug procurement policies and intense competition in the market for certain non-procurement products [2] Cost and Profitability - The gross profit, calculated as revenue minus operating costs, is insufficient to cover sales, management, and research and development expenses, leading to a challenging financial situation for the company [2] - The direct cause of the performance decline is identified as a significant drop in sales prices [2]

Group 1 - The company announced a provision for asset impairment losses totaling approximately 59.49 million yuan for the year 2025, which will reduce the net profit attributable to shareholders by about 55.07 million yuan after considering the impact of deferred income tax expenses of approximately 4.43 million yuan [1] - The asset write-off and disposal will further decrease the net profit attributable to shareholders by a total of approximately 24.32 million yuan, impacting shareholders' equity by the same amount and affecting cash flow by about 540,000 yuan [1] - Overall, the total expected reduction in the company's net profit for 2025 due to the asset impairment provision and asset write-off is approximately 79.39 million yuan [1] Group 2 - The industry is witnessing significant advancements in battery technology, with semi-solid-state batteries expected to be equipped in multiple new vehicles this year, indicating a year of iteration for power battery technology [1]

Group 1 - The company expects a net profit attributable to shareholders for the year 2025 to be between -375 million and -315 million yuan [1] - The net profit after deducting non-recurring gains and losses is also projected to be between -375 million and -315 million yuan [1] - The main reasons for the performance change include a decrease in sales prices, operating costs and period expenses remaining at the same level as the previous year, and the provision for significant credit impairment losses and non-recurring gains and losses [1]

（记者 王瀚黎） 每经头条（nbdtoutiao）——从极寒测试到万套装车！半固态电池今年有望搭载多款新车：各大厂商摩 拳擦掌，动力电池技术迎来迭代年 每经AI快讯，哈三联1月28日晚间发布公告称，公司第五届第二次董事会会议于2026年1月28日以通讯 表决的方式召开。会议审议了《关于2026年度日常关联交易预计的议案》等文件。 ...

哈三联（002900）(002900.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损3.15亿元 至3.75亿元;扣除非经常性损益后的净亏损3.15亿元至3.75亿元。 ...

智通财经APP讯，哈三联(002900.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损 3.15亿元至3.75亿元;扣除非经常性损益后的净亏损3.15亿元至3.75亿元。 ...

哈三联公告称，公司于2026年1月28日审议通过相关议案，对存在减值迹象的应收账款、预付账款、存 货等计提减值准备5949.14万元，对无使用价值的存货和固定资产进行核销。对科莱维及其子公司 2462.60万元预付账款全额计提减值 。存货销毁、固定资产处置、开发支出计研发费用涉及账面价值4亿 余元。本次计提及核销减少2025年净利润7938.67万元，仅现金流量影响涉及54.06万元。事项待会计师 事务所审计，审计委认为该事项符合规定、公允反映资产状况。 ...

哈三联公告称，2025年预计营收7.90亿元，同比下降3.43亿元，降幅30%；归属于上市公司股东的净利 润为-3.75亿元至-3.15亿元，同比下降739.11% - 636.85%，上年同期为5867.52万元。业绩下滑主因销售 单价下降，产品价格大幅降低，毛利难覆盖期间费用，且计提存货资产减值损失近3800万元。此外，营 业成本及费用增加、计提大额信用减值、非经常性损益等也影响业绩。 ...

Core Viewpoint - The company, 哈三联, is forecasting a significant net loss for the year 2025, with expected losses ranging from 315 million to 375 million yuan, primarily due to declining sales prices and increased costs [1] Group 1: Financial Performance - The projected total revenue for 2025 is expected to be 790 million yuan, representing a year-on-year decrease of 343 million yuan, or 30% [1] - The gross profit after deducting operating costs is insufficient to cover selling, administrative, and R&D expenses due to the decline in product sales prices while unit costs remain stable [1] Group 2: Cost and Expense Analysis - Sales expenses are expected to increase by over 23.5 million yuan, attributed to higher investments in the health sector and the establishment of a new office in Hangzhou [1] - Depreciation expenses are projected to rise by over 31 million yuan due to the completion of construction projects [1] - Losses from inventory write-offs are anticipated to increase by approximately 14.5 million yuan, mainly due to expired inventory and production inefficiencies [1] - Financial expenses are expected to rise by over 15 million yuan [1] Group 3: Impairment and Non-Recurring Losses - The company plans to fully recognize a significant credit impairment loss of 24.626 million yuan related to transactions with specific partners [1] - Non-recurring losses include approximately 7 million yuan from asset disposals and a fair value loss of 11.31 million yuan from investments in a Hong Kong stock [1]